首页> 外文期刊>Pakistan journal of medical sciences. >Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer
【24h】

Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer

机译:培美曲塞和顺铂序贯放化疗对局部晚期喉癌的治疗作用

获取原文
           

摘要

Objective: To explore the therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer (LALC).Methods: Fifty LALC patients who were treated in our hospital between January 2010 and January 2012 were selected and randomly divided into an observation group and a control group (n=25). The two groups were given conventional radiotherapy in the same manner, before which two cycles of chemotherapy were performed. The observation group intravenously infused with 500 mg/m2 pemetrexed on d1 and 25 mg/m2 cisplatin on d1-3, with 28 days as a cycle. The control group was intravenously infused with 25 mg/m2 cisplatin on d1-3 and 400 mg/m2 fluorouracil, with 28 days as a cycle. The short-term effects and adverse reactions of both groups were observed after treatment, and their survival was observed by follow-up for five years.Results: The response rate was 84% (21/25) in the observation group and 64% (16/25) in the control group, between which the difference was statistically significant (P0.05). The incidence of long-term adverse reactions such as grade III-IV laryngeal edemas, laryngeal cartilage inflammation and laryngeal cartilage necrosis showed no significant differences between the two groups (P>0.05). The median survival was 3.3 years after PC chemotherapy and 2.8 years after PF chemotherapy, between which the difference was not statistically significant (P>0.05). The levels of serum tumor markers significantly decreased after PC and PF treatments compared with those before (P<0.05).Conclusion: Combining PC chemotherapy with radiotherapy has satisfactory short-term therapeutic effects on LALC, and the resulting adverse effects can be tolerated. Therefore, this strategy is worthy of promotion and application in clinical practice.doi: http://dx.doi.org/10.12669/pjms.325.10640How to cite this:Tao Y, Ma C, Yin X, Fang X, Liu L. Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer. Pak J Med Sci. 2016;32(5):1126-1130. doi: http://dx.doi.org/10.12669/pjms.325.10640This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译:目的:探讨培美曲塞和顺铂序贯放化疗对局部晚期喉癌(LALC)的治疗效果。方法:选择2010年1月至2012年1月在我院就诊的50例LALC患者,随机分为观察组和观察组。对照组(n = 25)。两组均以相同的方式接受常规放疗,然后进行两个疗程的化疗。观察组在第1天静脉注射500 mg / m2培美曲塞,第1-3天静脉注射25 mg / m2顺铂。对照组在d1-3静脉输注25 mg / m2顺铂和400 mg / m2氟尿嘧啶静脉注射,周期为28天。观察两组治疗后的近期疗效及不良反应,并随访5年,观察其生存情况。结果:观察组有效率84%(21/25),有效率64%(21/25)。对照组)(16/25),两者之间的差异具有统计学意义(P0.05)。长期不良反应的发生率,如Ⅲ-Ⅳ级喉水肿,喉软骨炎症和喉软骨坏死,两组之间无显着性差异(P> 0.05)。 PC化疗后中位生存期为3.3年,PF化疗后中位生存期为2.8年,两者之间的差异无统计学意义(P> 0.05)。结论PC化疗联合放疗对LALC的近期疗效满意,可耐受PC和PF治疗后的血清肿瘤标志物水平(P <0.05)。因此,该策略值得在临床实践中推广应用。doi:http://dx.doi.org/10.12669/pjms.325.10640引用方式:陶Y,Ma C,Yin X,Fang X,Liu L培美曲塞和顺铂序贯放化疗对局部晚期喉癌的治疗效果。朴J医学。 2016; 32(5):1126-1130。 doi:http://dx.doi.org/10.12669/pjms.325.10640这是根据知识共享署名许可(http://creativecommons.org/licenses/by/3.0)的条款分发的开放访问文章,只要适当引用了原始作品,便可以在任何介质中不受限制地使用,分发和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号